Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Memphasys Ltd ( (AU:MEM) ) has issued an announcement.
Memphasys Limited has requested a trading halt on its securities pending an announcement regarding the results of its 2-year Felix™ System clinical trial. The trading halt is intended to ensure an orderly market, and the company expects to release the announcement before the commencement of trading on March 24, 2025.
More about Memphasys Ltd
Memphasys Limited operates in the biotechnology industry, focusing on reproductive biotechnology solutions. The company’s primary product is the Felix™ System, which is designed to enhance sperm selection for assisted reproductive technologies.
Average Trading Volume: 10,181,599
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$12.4M
See more insights into MEM stock on TipRanks’ Stock Analysis page.